Two isozymes of the cytochrome-P450-dependent drug oxidizing system exhibit polymorphism. Five to 10% of a Caucasian population are deficient in debrisoquine-hydroxylase activity and about 3% in mephenytoin-hydroxylase activity (poor metabolizers). We tested the hypothesis of a possible over-representation of poor metabolizers among patients with cluster headache. The individual metabolic capacity was determined in 30 cluster headache patients after administration of a test dose of 10 mg of debrisoquine and 100 mg of mephenytoin. Two patients (6.7%) were poor metabolizers of debrisoquine and one (3.3%) a poor metabolizer of mephenytoin. This was no different from the rate of poor metabolizers, 7.1% and 3.3% respectively, in a reference panel of healthy Swedish volunteers.
EkbomKHardeboJEWaldenlindEMechanisms of cluster headache. In:OlesenJEdvinssonL edsBasic mechanisms of headache.Amsterdam:Elsevier1988:46376
2.
MahgoubAIdleJRDringLGLancasterRSmithRLPolymorphic hydroxylation of debrisoquine in man.Lancet1977;2:584–6
3.
AlvanGBechtelPIseliusLGundert-RemyUHydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.Eur J Clin Pharmacol1990;39:533–7
4.
AyeshRIdleJRRitchieJCCrothersMJHerzelMRMetabolic oxidation phenotypes as markers for susceptibility to lung cancer.Nature1984;312:169–70
5.
BarbeauACloutierTRoyMPlasseLParisSPoirierJEcogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.Lancet1985a;ii:121316
6.
GudjonssonOSanzE.AlvanGAquiloniusS-MReviriegoJPoor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease.Br J Clin Pharmacol1990;30:301–2
7.
NiznikHBTyndaleRFSalleeFRGonzalezFJHardwickJInabaTKalowWThe dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3-H]GBR-12935 binding proteins.Arch Biochem Biophys1990;276:424–32
8.
BertilssonLAlmCDe Las CarrerasCWidenJEdmanGSchallingDDebrisoquine hydroxylation polymorphism and personality.Lancet1989;ii:555
9.
LlerenaAEdmanGCobaledaJAlmCBenitézJSchallingDBertilssonLPersonality and debrisoquine hydroxylation phenotypes in a Spanish population.Abstract, 6th International Meeting on Clinical Pharmacology in Psychiatry, Geneva,5--7 June 1991
10.
AmeryWKDaviesPTGCaersLIHeykantsJSteinerTJWoestenborghsRClifford RoseFHepatic cytochrome P450-mediated oxidation function in migraine.Cephalalgia1988;8:71–4
11.
DahlöfCAlmCBertlingIBarterLCytochromo-P450-dependent hydroxylation in migraine.This issue
12.
LeviREdmanGEkbomKSchallingDWaldenlindEPersonality characteristics and addictive behaviour in cluster headache. In:Clifford RoseF edNew advances in headache research: 2 Smith-Gordon 1991:2314
13.
SanzEJVillénTAlmCBertilssonLS-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine.Clin Pharmacol Ther1989;45:495–9
14.
The Headache Classification Committee of the International Headache Society:classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.Cephalalgia1988;8(suppl 7):196
15.
LennardMSSilarJHSmithAJTuckerGTDetermination of debrisoquine and its 4-hydroxymetabolite in biologic fluids by gas chromatography with flame-ionization and nitrogen-selective detection.J Chromatogr1977;133:161–8
16.
WedlundPJSweetmanBJMcAllisterCBBranchRAWilkinsonGRDirect enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography.J Chromatogr1984;307:121–7
17.
18.
SandercockPThe odds ratio: a useful tool in neurosciences.J Neurol Neurosurg Psychiatry1989;52:817–20
19.
WaldenlindESääfJEkbomKRossSWahlundL-OWetterbergLKinetics and thermolability of platelet monoamine oxidase in cluster headache and migraine.Cephalalgia1984;4:125–34
20.
HardeboJEEkmanR,Substance P and opioids in cluster headache. In:SicuteriFVecchietLFanciullacciM edsTrends in cluster headache.Amsterdam:Elsevier1987:14558
21.
BrøsenKGramLFClinical significance of the sparteine/debrisoquine oxidation polymorphism.Eur J Clin Pharmacol1989;36:537–47
22.
YueQ-YSvenssonJ-OAlmCSjöqvistFSäweJCodeine O-demethylation co-segregates with polymorphic debriso-quine hydroxylation.Br J Clin Pharmacol1989;28:639–45
23.
KalowWTyndaleRFDebrisoquine/sparteine monooxygenase and other P-450s in brain.The international encyclopedia of pharmacology and therapeutics.In press
24.
BertilssonLHenthornTSanzETybringGSäweJVillénTImportance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype.Clin Pharmacol Ther1989;45:348–55
25.
SanzEJBertilssonLd-propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.Ther Drug Monit1990:12:2979
